Ontology highlight
ABSTRACT: Background
The last decade has seen the increasing use of biological medicines in combination with chemotherapy containing 5-fluorouracil/oxaliplatin or irinotecan for the treatment of metastatic colorectal cancer (mCRC). These combinations have resulted in increased progression-free survival (PFS) in patients with mCRC; however, there are remaining concerns over the extent of their effect on overall survival (OS). Published studies to date suggest no major differences between the three currently available monoclonal antibodies (MoAbs); however, there are differences in costs. In addition, there is rising litigation in Brazil in order to access these medicines as they are currently not reimbursed.Objective
The aim was to investigate the comparative effectiveness and safety
SUBMITTER: da Silva WC
PROVIDER: S-EPMC6290722 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature